Drug
MMF Immunosuppression
MMF Immunosuppression is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph early_phase_1
3
75%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
3(100.0%)
Highest Phase Reached
Early Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Other(3)
Detailed Status
Suspended3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 13 (100.0%)
Trials by Status
recruiting125%
suspended375%
Recent Activity
1 active trials
Showing 4 of 4
suspendedearly_phase_1
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
NCT06662227
suspendedearly_phase_1
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
NCT06663046
suspendedearly_phase_1
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
NCT06653023
recruiting
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
NCT07491523
Clinical Trials (4)
Showing 4 of 4 trials
NCT06662227Early Phase 1
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
NCT06663046Early Phase 1
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
NCT06653023Early Phase 1
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
NCT07491523
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4